» Articles » PMID: 2292533

In-vitro Activity of Cefpodoxime Against 1834 Isolates from Domiciliary Infections at 20 UK Centres

Overview
Date 1990 Dec 1
PMID 2292533
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

A total of 1834 non-copy, general practice or outpatient isolates were collected by 20 hospital laboratories within the British Isles, and identified and tested for susceptibility to nine antimicrobial agents available by oral administration at one centre. Against Enterobacteriaceae cefpodoxime was the most active beta-lactam agent tested, the MIC90s being: for Escherichia coli 1.0 mg/l, for Proteus mirabilis 1.0 mg/l, for Citrobacter spp. 2.0 mg/l, and for Enterobacter spp., Serratia spp., Morganella spp. and Klebsiella spp. 16-64 mg/l. Cefpodoxime also showed a certain amount of activity against staphylococci and high activity against streptococci, the MIC90s being for Staphylococcus aureus 2 mg/l, for coagulase negative staphylococci 8 mg/l, for Streptococcus pyogenes 0.015 mg/l, for Str. pneumoniae 0.06 mg/l and for Str. agalactiae 0.5 mg/l.

Citing Articles

Cephalosporin utilisation review and evaluation.

Misan G, Dollman C, Shaw D, Burgess N Pharmacoeconomics. 1995; 8(2):100-22.

PMID: 10155606 DOI: 10.2165/00019053-199508020-00003.


In vitro methods for confirming reduced susceptibility to cefuroxime among Haemophilus influenzae isolates.

MacGowan A, Wootton M, James P, Bowker K, HOLT H, Reeves D Eur J Clin Microbiol Infect Dis. 1997; 16(4):328-9.

PMID: 9177974 DOI: 10.1007/BF01695645.


Cefpodoxime proxetil in the treatment of lower respiratory tract infections.

Geddes A Drugs. 1991; 42 Suppl 3:34-40.

PMID: 1726206 DOI: 10.2165/00003495-199100423-00008.


Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Frampton J, Brogden R, Langtry H, Buckley M Drugs. 1992; 44(5):889-917.

PMID: 1280571 DOI: 10.2165/00003495-199244050-00011.